Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Japanese (NIKKEI) Pharma Industry Analysis

UpdatedApr 11, 2026
DataAggregated Company Financials
Companies41
  • 7D-1.8%
  • 3M3.7%
  • 1Y39.7%
  • YTD5.5%

Over the last 7 days, the Pharma industry has dropped 1.8%, driven by Otsuka Holdings declining 5.1%. This takes the industry's 12 month performance to a gain of 40%. Earnings are forecast to grow by 8.8% annually.

Industry Valuation and Performance

Has the Japanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 11 Apr 2026JP¥49.7tJP¥17.3tJP¥2.2t15.8x22.8x2.9x
Mon, 09 Mar 2026JP¥50.4tJP¥17.3tJP¥2.2t15.1x23.1x2.9x
Wed, 04 Feb 2026JP¥48.0tJP¥17.1tJP¥2.0t16.6x23.5x2.8x
Fri, 02 Jan 2026JP¥45.9tJP¥16.9tJP¥1.9t16.5x24.1x2.7x
Sun, 30 Nov 2025JP¥46.3tJP¥16.9tJP¥1.9t16.1x24.3x2.7x
Tue, 28 Oct 2025JP¥41.7tJP¥16.8tJP¥1.8t15.3x22.8x2.5x
Thu, 25 Sep 2025JP¥41.0tJP¥16.8tJP¥1.8t16.2x22.4x2.4x
Sat, 23 Aug 2025JP¥40.9tJP¥16.8tJP¥1.8t15.9x22.3x2.4x
Mon, 21 Jul 2025JP¥39.9tJP¥16.8tJP¥1.8t16.7x22.7x2.4x
Wed, 18 Jun 2025JP¥40.3tJP¥16.8tJP¥1.8t15.2x22.8x2.4x
Fri, 16 May 2025JP¥38.8tJP¥16.8tJP¥1.8t13.8x21.8x2.3x
Sun, 13 Apr 2025JP¥35.6tJP¥16.5tJP¥1.5t13.8x23.6x2.2x
Tue, 11 Mar 2025JP¥39.6tJP¥16.5tJP¥1.5t15.9x26.3x2.4x
Thu, 06 Feb 2025JP¥39.8tJP¥16.3tJP¥1.3t13.7x30.5x2.4x
Sat, 04 Jan 2025JP¥42.2tJP¥16.1tJP¥1.4t16.2x29.9x2.6x
Mon, 02 Dec 2024JP¥42.4tJP¥16.1tJP¥1.4t15.6x30x2.6x
Wed, 30 Oct 2024JP¥46.0tJP¥15.6tJP¥1.2t16.2x37.1x2.9x
Fri, 27 Sep 2024JP¥44.5tJP¥15.5tJP¥1.2t16.2x37x2.9x
Sun, 25 Aug 2024JP¥48.0tJP¥15.5tJP¥1.2t17.6x40x3.1x
Tue, 23 Jul 2024JP¥44.5tJP¥15.0tJP¥1.1t18.4x40.6x3x
Thu, 20 Jun 2024JP¥40.1tJP¥15.0tJP¥1.1t17.9x36.7x2.7x
Sat, 18 May 2024JP¥41.1tJP¥15.0tJP¥1.1t16.8x37.7x2.7x
Mon, 15 Apr 2024JP¥39.9tJP¥14.8tJP¥1.2t19.1x33x2.7x
Wed, 13 Mar 2024JP¥43.2tJP¥15.1tJP¥1.2t19.6x35.6x2.9x
Fri, 09 Feb 2024JP¥40.9tJP¥15.0tJP¥1.3t21.9x32.6x2.7x
Sun, 07 Jan 2024JP¥40.0tJP¥15.2tJP¥1.4t19.7x29.1x2.6x
Tue, 05 Dec 2023JP¥39.9tJP¥15.2tJP¥1.4t20.1x29x2.6x
Thu, 02 Nov 2023JP¥38.9tJP¥15.1tJP¥1.4t23.9x28.3x2.6x
Sat, 30 Sep 2023JP¥40.4tJP¥14.9tJP¥1.4t23.9x28.3x2.7x
Mon, 28 Aug 2023JP¥40.0tJP¥14.9tJP¥1.4t22.9x28x2.7x
Wed, 26 Jul 2023JP¥38.5tJP¥14.6tJP¥1.5t20.8x26.3x2.6x
Fri, 23 Jun 2023JP¥41.3tJP¥14.6tJP¥1.5t20.5x28.2x2.8x
Sun, 21 May 2023JP¥39.9tJP¥14.6tJP¥1.5t19.7x27.3x2.7x
Tue, 18 Apr 2023JP¥38.2tJP¥14.3tJP¥1.5t17.6x26x2.7x
Price to Earnings Ratio

26x


Total Market Cap: JP¥38.2tTotal Earnings: JP¥1.5tTotal Revenue: JP¥14.3tTotal Market Cap vs Earnings and Revenue0%0%0%
Japanese Pharma Industry Price to Earnings3Y Average 28.6x202420252026
Current Industry PE
  • Investors are pessimistic on the Japanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 22.8x which is lower than its 3-year average PE of 28.6x.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 14% per year over the last three years.
  • Revenues for these companies have grown 6.4% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Japanese Healthcare industry?

JP Market2.88%
Healthcare-0.48%
Pharma-1.82%
Pharma-1.82%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
4503 Astellas PharmaJP¥2.61k0.8%
+JP¥35.8b		105.4%PE14.5x
4506 Sumitomo PharmaJP¥2.04k0.9%
+JP¥7.2b		295.3%PE7.4x
4888 Stella PharmaJP¥720.0022.7%
+JP¥4.5b		120.9%PS25.3x
4553 Towa PharmaceuticalJP¥4.26k1.9%
+JP¥3.9b		76.4%PE9.8x
4886 ASKA Pharmaceutical HoldingsLtdJP¥2.73k5.0%
+JP¥3.7b		21.7%PE15.8x

Latest News

4528
JP¥2,509.50
Ono Pharmaceutical
7D
-0.9%
1Y
54.2%
4568
JP¥2,772.50
Daiichi Sankyo Company
7D
-3.2%
1Y
-10.7%

4568: Oncology Approvals And Priority Reviews Will Drive Future Upside Potential

Analysts have kept their ¥6,000 price target for Daiichi Sankyo unchanged, citing slightly adjusted views on revenue growth, profit margins, and future P/E assumptions as they refine their outlook on the company. What's in the News ENHERTU (trastuzumab deruxtecan) has been approved in Japan for HER2 positive advanced or recurrent solid cancers that are refractory or intolerant to standard treatments, supported by multiple phase 2 trials and accompanied by an interstitial lung disease warning in the prescribing information (Product related announcements).
4507
JP¥3,371.00
Shionogi
7D
-5.4%
1Y
56.2%
4519
JP¥8,675.00
Chugai Pharmaceutical
7D
-1.2%
1Y
38.0%

4519: Rich P/E And Trial Setbacks Will Likely Restrain Future Upside

Analysts kept the fair value estimate for Chugai Pharmaceutical steady at ¥6,400. The unchanged price target is supported by updated assumptions that include revenue growth of 4.75%, a profit margin of 38.11% and a future P/E of 22.01x.
4503
JP¥2,607.00
Astellas Pharma
7D
0.8%
1Y
105.4%
4502
JP¥5,732.00
Takeda Pharmaceutical
7D
-1.2%
1Y
45.7%

Pipeline Progress And New Launches Will Secure Durable Long Term Earnings Power

Catalysts About Takeda Pharmaceutical Takeda Pharmaceutical is a global R&D driven biopharmaceutical company focused on specialty medicines across areas such as gastroenterology, rare diseases, plasma derived therapies, oncology, neuroscience and vaccines. What are the underlying business or industry changes driving this perspective?
4553
JP¥4,255.00
Towa Pharmaceutical
7D
1.9%
1Y
76.4%
4578
JP¥10,650.00
Otsuka Holdings
7D
-5.1%
1Y
58.4%

4578: Future Repricing Will Rely On Morgan Stanley Upgrade Momentum

Analysts have fine tuned their view on Otsuka Holdings, trimming the price target slightly from about ¥14,603 to around ¥14,480. This reflects updated assumptions for revenue growth, profit margins and a modestly lower future P/E multiple following recent research commentary, including the Morgan Stanley upgrade rationale.
4579
JP¥821.00
RaQualia Pharma
7D
3.8%
1Y
147.3%
4506
JP¥2,040.00
Sumitomo Pharma
7D
0.9%
1Y
295.3%
4565
JP¥1,021.00
Nxera Pharma
7D
1.6%
1Y
40.8%
4516
JP¥5,152.00
Nippon Shinyaku
7D
-3.0%
1Y
50.4%
4886
JP¥2,734.00
ASKA Pharmaceutical HoldingsLtd
7D
5.0%
1Y
21.7%
4559
JP¥2,304.00
Zeria Pharmaceutical
7D
0.7%
1Y
5.5%
4151
JP¥2,566.00
Kyowa Kirin
7D
-1.3%
1Y
23.1%
4888
JP¥720.00
Stella Pharma
7D
22.7%
1Y
120.9%